Session

IBD (Posters)

INTEGRATION OF EHEALTH FOR PAEDIATRIC IBD IN REAL LIFE IS SAFE
INTEGRATION OF EHEALTH FOR PAEDIATRIC IBD IN REAL LIFE IS SAFE

IBD (Posters)  et al.

VEDOLIZUMAB IV VERSUS ADALIMUMAB TO TREAT MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: COST-EFFECTIVENESS FROM A US PRIVATE PAYER PERSPECTIVE
VEDOLIZUMAB IV VERSUS ADALIMUMAB TO TREAT MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: COST-EFFECTIVENESS FROM A US PRIVATE PAYER PERSPECTIVE

IBD (Posters)  et al.

A MACHINE LEARNING APPROACH IDENTIFIES SPECIFIC MICROBIOTA SIGNATURE ASSOCIATED TO VARIOUS DEGREE OF ULCERATIVE COLITIS
A MACHINE LEARNING APPROACH IDENTIFIES SPECIFIC MICROBIOTA SIGNATURE ASSOCIATED TO VARIOUS DEGREE OF ULCERATIVE COLITIS

IBD (Posters)  et al.

INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY
INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY

IBD (Posters)  et al.

CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY
CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY

IBD (Posters)  et al.

MANAGEMENT AND UNMET NEED AMONGST MILD AND MODERATE/ SEVERE CD AND UC PATIENTS: FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)
MANAGEMENT AND UNMET NEED AMONGST MILD AND MODERATE/ SEVERE CD AND UC PATIENTS: FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)

IBD (Posters)  et al.

INTRODUCTION OF BOWEL ULTRASONOGRAPHY FOR FOLLOW-UP OF PEDIATRIC INFLAMMATORY BOWEL DISEASE: A SINGLE-CENTER EXPERIENCE
INTRODUCTION OF BOWEL ULTRASONOGRAPHY FOR FOLLOW-UP OF PEDIATRIC INFLAMMATORY BOWEL DISEASE: A SINGLE-CENTER EXPERIENCE

IBD (Posters)  et al.

PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC
PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC

IBD (Posters)  et al.

TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

IBD (Posters)  et al.

INFLUENCE OF THE INTERVAL OF TIME BETWEEN ANTI-TNF AND VEDOLIZUMAB OR USTEKINUMAB IN THE RESPONSE TO TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
INFLUENCE OF THE INTERVAL OF TIME BETWEEN ANTI-TNF AND VEDOLIZUMAB OR USTEKINUMAB IN THE RESPONSE TO TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

THE JAK-3 AND TYK-2 / STAT PATHWAYS ARE ACTIVATED IN MODERATE TO SEVERE ULCERATIVE COLITIS
THE JAK-3 AND TYK-2 / STAT PATHWAYS ARE ACTIVATED IN MODERATE TO SEVERE ULCERATIVE COLITIS

IBD (Posters)  et al.

QUALITY OF LIFE OUTCOMES FROM PURSUIT-M TRIAL FURTHER SUPPORT EARLY DOSE OPTIMIZATION OF GOLIMUMAB IN MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS
QUALITY OF LIFE OUTCOMES FROM PURSUIT-M TRIAL FURTHER SUPPORT EARLY DOSE OPTIMIZATION OF GOLIMUMAB IN MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS

IBD (Posters)  et al.

PREDICTION OF INFLAMMATORY BOWEL DISEASE COURSE BASED ON FAECAL VOLATILE ORGANIC COMPOUNDS
PREDICTION OF INFLAMMATORY BOWEL DISEASE COURSE BASED ON FAECAL VOLATILE ORGANIC COMPOUNDS

IBD (Posters)  et al.

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY
EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

IBD (Posters)  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

IBD (Posters)  et al.

ANTI-USTEKINUMAB ANTIBODIES USING A DRUG TOLERANT ASSAY IS THE ONLY PREDICTIVE FACTOR OF CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENT UNDER USTEKINUMAB
ANTI-USTEKINUMAB ANTIBODIES USING A DRUG TOLERANT ASSAY IS THE ONLY PREDICTIVE FACTOR OF CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENT UNDER USTEKINUMAB

IBD (Posters)  et al.

CORTICOSTEROID USE AND THE ASSOCIATED IMPACT ON PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC) IN THE US, FRANCE, GERMANY, ITALY, SPAIN, AND UK (EU5)
CORTICOSTEROID USE AND THE ASSOCIATED IMPACT ON PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC) IN THE US, FRANCE, GERMANY, ITALY, SPAIN, AND UK (EU5)

IBD (Posters)  et al.

HUMANISTIC BURDEN AND IMPACT OF THE DISEASE IN MODERATE TO SEVERE PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC): FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)
HUMANISTIC BURDEN AND IMPACT OF THE DISEASE IN MODERATE TO SEVERE PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC): FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)

IBD (Posters)  et al.

THE RISK OF LATER DEVELOPING INFLAMMATORY BOWEL DISEASE IN SUBJECTS WITH DERMATOLOGICAL DISORDERS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE
THE RISK OF LATER DEVELOPING INFLAMMATORY BOWEL DISEASE IN SUBJECTS WITH DERMATOLOGICAL DISORDERS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

THE RISK OF LATER DEVELOPING INFLAMMATORY BOWEL DISEASE IN SUBJECTS WITH OPHTHALMIC DISORDERS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE
THE RISK OF LATER DEVELOPING INFLAMMATORY BOWEL DISEASE IN SUBJECTS WITH OPHTHALMIC DISORDERS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

Item 1 - 20 / 279
1
2 3 4 5 6 7 8 9 10 11 12 13 14